Q-omics provides the consensus-scored TREH profile across patient tissues and cancer cell-line models. TREH expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TREH is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, TREH RNA expression shows 15,816 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, and TGCT as cancer lineages where TREH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TREH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TREH survival associations across molecular data types. TREH RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TREH RNA expression–survival associations across cancer types. High TREH expression shows unfavorable associations in ACC, UVM and MESO, but favorable associations in KIRP, KIRC and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TREH RNA expression.
This table summarizes TREH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TREH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TREH shows lower tumor expression in KIRP, KICH, HNSC, KIRC, BLCA and COAD. The KIRP box plot shows higher TREH RNA expression in normal versus tumor tissue (log2 FC = −3.762, t-test p < 0.001).
This table shows molecular features associated with TREH in patient tissues and cancer cell lines. In patient samples, TREH shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TREH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
